5-(p-Chlorphenyl)-3-morpholino-4-phenyl-1,2,4-triazol | 32539-71-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 5-(p-Chlorphenyl)-3-morpholino-4-phenyl-1,2,4-triazol
• 英文别名: 4-[5-(4-chloro-phenyl)-4-phenyl-4H-[1,2,4]triazol-3-yl]-morpholine；4-[5-(4-Chlorophenyl)-4-phenyl-1,2,4-triazol-3-yl]morpholine
• CAS: 32539-71-2
• 化学式: C₁₈H₁₇ClN₄O
• 分子量: 340.812
• InChiKey: NPFQMRVODJKPRD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  43.2
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• Cooling adjunct for medications to treat disorders in the nasal cavity
  申请人：Wei Edward Tak

  公开号：US10722477B2

  公开（公告）日：2020-07-28

  The present discovery pertains generally to the field of therapeutic compounds. More specifically the present discovery pertains to certain di-alkyl-phosphinoyl-alkanes as described herein, DIPA-1-8 and DIPA-1-9, and 2-6 and 2-7 that are collectively referred to herein as “DAPA compounds”, that are useful in the treatment of disorders (e.g., diseases) including: sensory discomfort (e.g., caused by inflammation, irritation, itch, or pain) in the nasal cavity. The applicant has found that localized delivery of DAPA compounds in combination with an intranasal steroid or an intranasal antihistamine immediately relieves nasal discomfort and enhances patient adherence to the use of the nasal medications.

  本发现一般涉及治疗化合物领域。更具体地说，本发现涉及本文所述的某些二烷基膦酰基烷烃、DIPA-1-8 和 DIPA-1-9，以及本文统称为 "DAPA 化合物 "的 2-6 和 2-7，这些化合物可用于治疗包括鼻腔感觉不适（如由炎症、刺激、瘙痒或疼痛引起）在内的紊乱（如疾病）。申请人发现，局部给药 DAPA 化合物与鼻内类固醇或鼻内抗组胺药结合使用，可立即缓解鼻腔不适，并提高患者使用鼻腔药物的依从性。
• Topical agents for the treatment of sensory discomfort in the nasal cavity
  申请人：Wei Edward T.

  公开号：US20150265752A1

  公开（公告）日：2015-09-24

  The present discovery pertains generally to the field of therapeutic compounds. More specifically the present discovery pertains to certain di-alkyl-phosphinoyl-alkanes as described herein, DIPA-1-8 and DIPA-1-9, and 2-6 and 2-7 that are collectively referred to herein as “DAPA compounds”, that are useful in the treatment of disorders (e.g., diseases) including: sensory discomfort (e.g., caused by inflammation, irritation, itch, or pain) in the nasal cavity. The applicant has found that localized delivery of DAPA compounds with a swab to the Kiesselbach's area of the human nose will relieve the discomforts of rhinitis and other nasal cavity discomforts.
• Cooling Adjunct For Medications To Treat Disorders In The Nasal Cavity
  申请人：Wei Edward Tak

  公开号：US20170296489A1

  公开（公告）日：2017-10-19

  The present discovery pertains generally to the field of therapeutic compounds. More specifically the present discovery pertains to certain di-alkyl-phosphinoyl-alkanes as described herein, DIPA-1-8 and DIPA-1-9, and 2-6 and 2-7 that are collectively referred to herein as “DAPA compounds”, that are useful in the treatment of disorders (e.g., diseases) including: sensory discomfort (e.g., caused by inflammation, irritation, itch, or pain) in the nasal cavity. The applicant has found that localized delivery of DAPA compounds in combination with an intranasal steroid or an intranasal antihistamine immediately relieves nasal discomfort and enhances patient adherence to the use of the nasal medications.
• US9642868B2
  申请人：——

  公开号：US9642868B2

  公开（公告）日：2017-05-09